This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Geron's the Biotech of the Day

Biotechs, notably smaller-cap names with experimental therapies, have been skyrocketing lately as investors have jumped on word of any development in their research or product prospects -- even though in many cases that product might still be a long way from commercial viability.

That trend was being reinforced again on Tuesday, as Geron (GERN - Get Report) saw its shares rise $1.72, or 25%, to $8.68 after the company said it has received a patent that could be used in stem-cell research. The process would be used, if it's ever needed, to provide an additional level of safety for cell therapies made from human embryonic stem cells, the company said.

Human embryonic stem cells can become any type of cell in the body. Potentially, they could be differentiated or harnassed to produce therapeutic cells to treat diseases. But if transplanted therapeutic cells contain undifferentiated cells, they can form cell types that aren't needed for the therapy. Geron's patent covers a technology used to eliminate the undifferentiated cells.

Geron traded as high as $9.75 earlier in the session, and it is still eclipsing the 52-week high of $7.40. More than 10 million shares have already traded, five times the normal volume for a full day.

Another company in this biotech subsector, StemCells (STEM - Get Report), was higher by 21 cents, or 10%, to $2.37. Meanwhile, the broader biotechnology group measures were ticking lower. The Amex Biotech Index was down 0.3%, and the Nasdaq Biotech Index was slipping 0.2%.

Among the other tiny biotechs going higher, Genaera (GENR) was adding 16% to $2.46 after receiving a patent; Aastrom Bioscience (ASTM) rose 17% to $1.41 as investors cheered a partnership involving bone grafts; and VaxGen (VXGN) was climbing nearly 17% to $5.94 on news the company received a National Institutes of Health grant to identify novel antigens that could be used in future HIV vaccine candidates.

Each new day seems to bring new big winners in the biotech field, and one of Monday's gainers, Oxigene (OXGN), was giving back some ground in the session currently under way. The stock, which added more than $5 yesterday to $13.80, was lately losing $1.66 to $12.14. The decline came after the company said it has reached an agreement to sell 1.5 million common shares at $10 each to three institutional investors. Before yesterday's run-up, Oxigene's 52-week high was $8.96.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
STEM $0.99 0.00%
GERN $3.85 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs